title: Predictors of remission from body dysmorphic disorder: a prospective study.
abstract: In the first naturalistic, prospective study of the course of body dysmorphic disorder (BDD), we examined predictors of remission in 161 subjects over 1 year of follow-up. Data were obtained on clinical characteristics at the intake interview and weekly BDD symptom severity over 1 year using the Longitudinal Interval Follow-Up Evaluation. More severe BDD at intake, longer BDD duration, and the presence of a comorbid personality disorder predicted a lower likelihood of partial or full remission from BDD. BDD remission was not predicted by gender; race/ethnicity; socioeconomic status; being an adult versus an adolescent; age of BDD onset; delusionality of BDD symptoms; or the presence at intake of major depression, a substance use disorder, social phobia, obsessive compulsive disorder, or an eating disorder. Receipt of mental health treatment or nonmental health treatment (e.g., surgery, dermatologic treatment) during the follow-up year also did not predict remission from BDD.
authors.affiliation: Brown Medical School, Providence, Rhode Island, USA.
authors.forename: Katharine A
authors.initials: KA
authors.lastname: Phillips
authors.forename: Maria E
authors.initials: ME
authors.lastname: Pagano
authors.forename: William
authors.initials: W
authors.lastname: Menard
authors.forename: Christina
authors.initials: C
authors.lastname: Fay
authors.forename: Robert L
authors.initials: RL
authors.lastname: Stout
mesh_terms: D000328:Adult; D015897:Comorbidity; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D017063:Outcome Assessment, Health Care; D010554:Personality Disorders / Q000453:epidemiology; D011446:Prospective Studies; D011613:Psychotherapy; D011619:Psychotropic Drugs; D013001:Somatoform Disorders / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D011619:Psychotropic Drugs